Bradykinin Receptor

Cat. No.

A13839

CAS No.

464930-42-5

SSR240612

SSR240612 is a new antagonist of the bradykinin B1 receptor.

Cat. No.

A12964

CAS No.

215258-13-2

FR167344 free base

Synonyms: FR 167344

FR167344 free base is an orally active, nonpeptide bradykinin receptor B2 antagonist.

Cat. No.

A18074

CAS No.

130308-48-4

Icatibant

Synonyms: Firazyr

Icatibant (HOE-140) is a selective and specific antagonist of bradykinin B2 receptor with IC50 and Ki of 1.07 nM and 0.798 nM respectively.

Cat. No.

A21207

CAS No.

913064-47-8

ELN-441958

ELN-441958 is a potent, neutral antagonist of B1 receptor, inhibits the binding of the B1 agonist ligand [3H]DAKD to IMR-90 cells with Ki of 0.26 nM.

Cat. No.

A23883

CAS No.

185052-09-9

R715

R715 is a selective bradykinin B1 receptor antagonist. R715 significantly attenuates the hyperalgesic effect developed in Streptozotocin-diabetic mice.

Cat. No.

A59123

CAS No.

151039-63-3

WIN 64338

WIN 64338 is a non-peptide antagonist of the bradykinin B2 receptor. It effectively inhibits bradykinin-evoked trigeminal nerve stimulation, making it valuable for research related to pain signaling pathways and inflammatory responses. This compound is relevant for studies investigating the role of bradykinin in various physiological and pathological states.

Cat. No.

A59127

CAS No.

209788-45-4

Anatibant hydrochloride

Synonyms: LF 16-0687 hydrochloride; XY-2405 hydrochloride

Anatibant hydrochloride is a selective non-peptide antagonist of the bradykinin B2 receptor. It exhibits high affinity binding to recombinant B2 receptors in human, rat, and guinea pig models, with Ki values of 0.67 nM, 1.74 nM, and 1.37 nM, respectively. Notably, Anatibant hydrochloride is capable of crossing the blood-brain barrier, making it a valuable tool for investigating pathophysiological conditions related to brain injury and neuroinflammation.

Cat. No.

A59131

CAS No.

2231142-90-6

Fulimetibant

Fulimetibant is a selective antagonist of bradykinin receptors, primarily B1 and B2 subtypes. This compound inhibits the action of bradykinin, a peptide involved in pain and inflammatory responses. Fulimetibant is utilized in research to investigate the role of bradykinin in various pathological conditions, including pain mechanisms and inflammation-related disorders.

Cat. No.

A59132

CAS No.

71800-37-8

Lys-(Des-Arg9,Leu8)-Bradykinin

Lys-(Des-Arg9,Leu8)-Bradykinin is a selective antagonist of the bradykinin B1 receptor. This compound inhibits bradykinin-mediated signaling pathways, making it valuable for studies focused on pain, inflammation, and vascular permeability. Its role in various experimental models facilitates the investigation of bradykinin's effects on physiological and pathological conditions.

Cat. No.

A59133

CAS No.

1119282-90-4

BI-113823

BI-113823 is a selective antagonist of the bradykinin B1 receptor, exhibiting oral bioactivity. It effectively alleviates mechanical hyperalgesia induced by complete Freund's adjuvant in animal models. This compound is relevant for research focused on chronic inflammatory pain mechanisms and potential therapeutic strategies.

Cat. No.

A59137

CAS No.

209733-45-9

Anatibant

Synonyms: LF 16-0687; XY-2405

Anatibant is a selective non-peptide antagonist of the bradykinin B2 receptor. It demonstrates high affinity for recombinant human, rat, and guinea-pig B2 receptors, with Ki values of 0.67 nM, 1.74 nM, and 1.37 nM, respectively. This compound effectively crosses the blood-brain barrier, making it a valuable tool for investigating the role of bradykinin signaling in brain damage diseases and related neuroinflammatory conditions.

Cat. No.

A59139

CAS No.

869939-83-3

Fasitibant free base

Fasitibant free base is a selective antagonist of the bradykinin B2 receptor, exhibiting high affinity and prolonged activity. This compound is primarily utilized in research focused on inflammatory pathways, particularly in the study of osteoarthritis and rheumatoid arthritis. Its ability to modulate proinflammatory responses makes it a valuable tool for investigating therapeutic approaches targeting these conditions.

Cat. No.

A59142

CAS No.

180981-09-3

B 9430

B 9430 is a potent antagonist of both bradykinin B1 and B2 receptors. By inhibiting these receptors, B 9430 plays a crucial role in modulating inflammatory responses and pain signaling pathways. This compound is applicable in research focused on cardiovascular diseases, pain management, and various inflammatory conditions.

Cat. No.

A59144

CAS No.

869880-33-1

Fasitibant chloride hydrochloride

Synonyms: MEN16132

Fasitibant chloride hydrochloride is a selective and high-affinity antagonist of the bradykinin B2 receptor, exhibiting potent and long-lasting activity. This compound is specifically investigated for its proinflammatory effects and is valuable in research focused on osteoarthritis and rheumatoid arthritis. Its mechanism offers insights into bradykinin-mediated pathways and potential therapeutic interventions in inflammatory conditions.

Cat. No.

A59147

CAS No.

103412-37-9

B4148

B4148 is a selective competitive antagonist of the bradykinin receptor, effectively blocking the action of bradykinin. This compound has been shown to significantly inhibit bradykinin-induced hypotension in rat models, particularly in the context of endotoxin shock induced by Escherichia coli lipopolysaccharide. Researchers can utilize B4148 to study vascular responses and blood pressure regulation under inflammatory conditions.

Cat. No.

A59149

CAS No.

1054763-33-5

[Des-Arg10]-HOE I40

[Des-Arg10]-HOE I40 is a potent antagonist of the bradykinin B1 receptor, known for its ability to inhibit bradykinin-induced signaling. This compound plays a significant role in research investigating inflammatory processes and pain pathways, particularly in conditions associated with bradykinin receptor activation. Its effectiveness in blocking B1 receptor activity makes it a valuable tool for studying the therapeutic potential in various pathological states.

Cat. No.

A59153

CAS No.

578727-81-8

Bradykinin B1 receptor antagonist 1

Bradykinin B1 receptor antagonist 1 is a selective antagonist of the bradykinin B1 receptor, notable for its ability to cross the blood-brain barrier. This compound exhibits efficacy in modulating pain pathways, making it a valuable tool for research into pain mechanisms and potential therapeutic interventions. Its unique action on the bradykinin B1 receptor complements studies focusing on inflammatory responses and pain management.

Cat. No.

A59157

CAS No.

147267-10-5

NPC 17731

NPC 17731 is a potent bradykinin (BK) receptor antagonist that effectively inhibits both contractile and relaxant responses induced by bradykinin. With an IC50 of 23 nM for contractile effects and 29 nM for relaxant effects, this compound serves as a valuable tool for studying bradykinin signaling pathways. Research applications include investigating cardiovascular responses and potential therapeutic strategies for conditions associated with bradykinin dysregulation.

Cat. No.

A59161

CAS No.

167838-64-4

FR173657

Synonyms: FK-3657

FR173657 is a potent orally active antagonist of the bradykinin B2 receptor, exhibiting IC50 values of 0.56, 1.5, and 2.9 nM for pig, rat, and human receptors, respectively. This compound effectively inhibits bradykinin-induced bronchoconstriction in guinea pigs with an ED50 of 0.075 mg/kg and demonstrates the ability to reduce carrageenan-induced paw edema in mice at an ED50 of 6.8 mg/kg. FR173657 is valuable for research into inflammatory diseases and related physiological responses.

Cat. No.

A59163

CAS No.

109333-26-8

NPC-567

NPC-567 is a potent bradykinin B2 receptor antagonist. This compound effectively inhibits the acute response to allergens in the airways, making it valuable for research in allergy and respiratory conditions. Its mechanism of action provides a useful tool for exploring the role of bradykinin signaling in inflammatory responses.

Cat. No.

A59168

CAS No.

163727-74-0

WIN 64338 hydrochloride

WIN 64338 hydrochloride is a selective, nonpeptide competitive antagonist of the bradykinin B2 receptor, effectively inhibiting [3H]-Bradykinin binding in human IMR-90 cells with a Ki value of 64 nM. Additionally, this compound demonstrates inhibitory effects on [3H]Quinuclidinyl benzilate binding to rat brain muscarinic receptors, with a Ki of 350 nM. Its ability to modulate bradykinin signaling positions WIN 64338 hydrochloride as a valuable tool for research in pain, inflammation, and cardiovascular studies.

Cat. No.

A59169

CAS No.

259885-54-6

BKM-570

BKM-570 is a nonpeptide bradykinin antagonist that exhibits significant anticancer properties. This compound is valuable for research applications focusing on lung, prostate, and ovarian cancers, providing insights into the role of bradykinin signaling in tumor biology and potential therapeutic approaches. Its antagonistic action contributes to the understanding of bradykinin's involvement in cancer progression.